Your doctor should assess several factors before approving discontinuation, including your current weight status and trajectory, the presence and control of obesity-related comorbidities (type 2 diabetes, hypertension, sleep apnea, cardiovascular disease), your readiness and capacity to implement intensive lifestyle modifications, available support systems and resources, and your history of weight cycling or previous weight loss attempts
Knowing the risks can help you make a more informed decision
Until recently, GLP-1RAs would have mostly been the purview of primary care physicians and endocrinologists
The FDA issued guidance stating that 503A compounding pharmacies had until April 22, 2025 to stop producing semaglutide injection products that were essentially copies of the commercially available drug
Since tolerability remains a hurdle in the widespread adoption of GLP-1 treatments, experts at the summit discussed the potential of these combination therapies to mitigate treatment side effects and improve patient adherence